Clinical review: Update of avian influenza A infections in humans

Table 7 Neuroaminidase inhibitors

	Oseltamivir	Zanamivir
Spectrum of activity	Influenza A and B	Influenza A and B
Administration	Oral	Inhalation
Prophylaxis	≥ 13 years; 75 mg daily	>13 years; 10 mg daily
Treatment	≥ 1 year; 75 BID × 5 to 10 days	≥ 7 years; 10 mg BID × 5 to 10 days
Select adverse effects	GI symptoms: N/V, abdominal pain	Bronchospasm, cough
Resistance potential	Drug-resistant strain of H5N1 reported	None yet
Efficacy	Estimated efficacy: 30 to 70 percent	Not well studied
Generic available	No	No

Data are from [80-82]. BID, twice a day; GI, gastrointestinal; N/V, nausea and vomiting.

ISSN: 1364-8535